{
  "id": "LSB10010",
  "type": "CRS Report Type LSB",
  "typeId": "LSB",
  "number": "LSB10010",
  "active": true,
  "source": "CRSReports.Congress.gov",
  "versions": [
    {
      "source_dir": "crsreports.congress.gov",
      "title": "All Eyes on Allergan: Drug Company\u2019s Unprecedented Move Raises Questions for Patent and Drug Law (Part II) ",
      "retrieved": "2020-09-05T09:17:22.200030",
      "id": "LSB10010_4_2017-10-12",
      "formats": [
        {
          "filename": "files/2017-10-12_LSB10010_19938baab152f257d82a592a68c47f5dd1a8df7e.pdf",
          "format": "PDF",
          "url": "https://crsreports.congress.gov/product/pdf/LSB/LSB10010/4",
          "sha1": "19938baab152f257d82a592a68c47f5dd1a8df7e"
        },
        {
          "format": "HTML",
          "filename": "files/2017-10-12_LSB10010_19938baab152f257d82a592a68c47f5dd1a8df7e.html"
        }
      ],
      "date": "2017-10-12",
      "summary": null,
      "source": "CRSReports.Congress.gov",
      "typeId": "LSB",
      "active": true,
      "sourceLink": "https://crsreports.congress.gov/product/details?prodcode=LSB10010",
      "type": "CRS Report Type LSB"
    }
  ],
  "topics": []
}